Navigation Links
Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008
Date:7/29/2008

9) (18,766)(9)

61,136 99,924

ADJUSTED NET INCOME $160,055 $170,801

BASIC ADJUSTED INCOME PER COMMON SHARE $2.36 $2.58

DILUTED ADJUSTED INCOME PER COMMON SHARE $2.15 $2.17

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING 67,721 66,127

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING-ASSUMING DILUTION 74,569 78,656

Notes to Reconciliation of GAAP Net Income to Adjusted Net Income

(1) To exclude the on-going amortization of acquired intangible assets

($53.0 million in 2008; $42.0 million in 2007), and accelerated

depreciation related to restructuring ($3.8 million in 2008).

(2) To exclude charges related to payments for several research and

development collaborations, as well as other charges ($1.8 million)

related to employee severance costs in 2008.

(3) To exclude charges related to employee severance costs.

(4) To exclude the reserve established for the minimum liability related

to the potential settlement of the investigations by the U.S.

Attorney's Office.

(5) To exclude the pre-tax gain related to the sale of certain

investments.

(6) To exclude an estimate of accrued interest related to the agreement

in principle reached with U.S. Attorney's Office in Philadelphia.

(7) To exclude costs related to the CIMA Labs restructuring announced in

January 2008.

(8) To exclude charges related to the acquisition of licensed technology

in the oncology field.

(9) To reflect the tax effect of pre-tax adjustments at the applicable

tax rates and certain other tax adjustments primarily related to

changes in valuation allowances
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 AACC, a global scientific and medical ... unveiled an updated brand identity today that reflects the ... changing healthcare environment and continue to do what they ... get the care they need. " ... an essential role in saving lives and making people ...
(Date:8/1/2014)... , August 1, 2014 According ... Research "Biophotonics Market - Global Industry Analysis, Size, Share, ... was valued at USD 25.16 billion in 2013, which ... growing at a CAGR of 10.4% from 2014 to ... at  http://www.transparencymarketresearch.com/biophotonics-market.html Increasing demand for accurate ...
(Date:8/1/2014)... Mass. (PRWEB) August 01, 2014 BCC ... RNAi DRUG DELIVERY: TECHNOLOGIES AND GLOBAL MARKETS , ... technologies is expected to grow to nearly $38.8 billion ... (CAGR) of 27.2%. The aptamer delivery category, the fastest ... phenomenal 58.2% CAGR. , The field of RNAi therapeutics ...
(Date:8/1/2014)... Testing the mechanical properties of microtissues ... embryonic development. How and why embryonic stem ... distinct tissues is important because abnormalities can lead ... Melissa Kinney, and Rabbia Saeed worked from the ... to control many aspects of embryo development. ...
Breaking Biology Technology:AACC Debuts Refreshed Brand Identity 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3Study Links Biomechanics and Gene Expression in Stem Cells 2
... long-awaited speaking faculty for the September Pharma ChemOutsourcing ... conference website reports Mark Alexay, President of Apaporis ... comprised of 100 speakers from pharmaceutical companies and ... the pipeline. The speaker list may be viewed ...
... Christine Lawless, MD, has accepted the position as ... continuing medical education (CME), beginning March 2, 2009. Recognized ... medicine cardiology, Dr. Lawless recently completed her clinical tenure ... where she was Associate Professor of Internal Medicine and ...
... Endpoints,NEW YORK, March 10 Intra-Cellular Therapies, Inc. today ... trial in patients with Sleep Maintenance Insomnia (SMI). ... wave sleep and decreased the duration of wake after ... prespecified primary and key secondary endpoints of the trial. ...
Cached Biology Technology:Pharma ChemOutsourcing Unveils 100 Pharma & Biotech Speaker Faculty for 2009 Conference September 14-16 in Long Branch, NJ 2Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise 2Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 2Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 3Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 4Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 5Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 6Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 7
(Date:8/1/2014)... 1, 2014Lesbian, gay, bisexual, and transgender individuals who want ... as some of their heterosexual and cisgendered peers, such ... additional physiological and legal challenges to become parents. ... assisted reproduction options is presented in the article " ... published in LGBT Health , a ...
(Date:8/1/2014)... group of marine mammals have officially named a ... Sousa sahulensis , according to the Wildlife ... study describing the newly named species is the ... all available historical records, physical descriptions, and genetic ... cetaceans ranging from the coast of West Africa ...
(Date:8/1/2014)... tricky enough. Knowing what causes them at the molecular ... Iowa researchers have created the most detailed map to ... associated with blinding diseases, such as age-related macular degeneration. ... the choroid, which supplies blood and oxygen to the ... in the abundance of proteins in different areas of ...
Breaking Biology News(10 mins):Advances in assisted reproduction create more options & new legal issues for LGBT couples 2Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3A map for eye disease 2
... A new technique for transplanting the ovaries of women ... cancer treatment was outlined to the 25th annual conference ... today (Monday 29 June). Dr. Pascal Piver, ... Limoges, France, described a new, two-step method of ovarian ...
... Shingu City, Japan--Deepsea Drilling Vessel CHIKYU has resumed IODP ... the Kii Peninsula of Japan. The scientific drilling expedition,s ... meters. Following sea floor surveys, the crew began fitting ... an upper section of the first borehole to be ...
... June 2009 Elsevier, the leading publisher of scientific, ... the highlights of its journal impact factor performance in ... factors (IF) increase from 2007 to 2008. According to ... journals took the #1 position in 51 categories (of ...
Cached Biology News:Ovarian transplantation: First baby is born after a new technique 2First riser-drilling research operations undertaken 2Elsevier announces 2008 journal impact factor highlights 2Elsevier announces 2008 journal impact factor highlights 3
... long electrophoresis hood is a ... systems. Placed on the transilluminator, ... place and provides a darkroom ... the lab bench. This 15.2 ...
... derived from frozen embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 7 ... are large (3-5 mm in diameter) in ...
... are derived from frozen embedded tissue blocks, ... procedures to ensure the highest quality. Tissues ... one block, sectioned at a thickness of ... are large (3-5mm in diameter) in comparison ...
... microarrays are derived from Paraffin embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5mm in diameter) ...
Biology Products: